var data={"title":"Ketoconazole (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ketoconazole (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389797?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ketoconazole-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ketoconazole (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=ketoconazole-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ketoconazole (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120384\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because ketoconazole tablets have been associated with serious adverse effects, ketoconazole tablets are not indicated for the treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections. Use ketoconazole only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious hepatotoxicity, including cases with a fatal outcome or requiring liver transplantation, has occurred with the use of oral ketoconazole. Some patients had no obvious risk factors for liver disease. Inform patients receiving this drug of the risk and closely monitor.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">QT prolongation and drug interactions leading to QT prolongation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Coadministration of the following drugs with ketoconazole is contraindicated: dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, and ranolazine. Ketoconazole can cause elevated plasma concentrations of these drugs and may prolong QT intervals, sometimes resulting in life-threatening ventricular dysrhythmias, such as torsades de pointes.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120609\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Ketoconazole;</li>\n      <li>Teva-Ketoconazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501727\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503653\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ketoconazole-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ketoconazole (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Fungal infections:</b> Children &ge;2 years and Adolescents: Oral: 3.3 to 6.6 mg/kg/day once daily; maximum daily dose: 400 mg/<b>day</b>; duration of therapy variable; continue therapy until active fungal infection has resolved (based on clinical and laboratory parameters); some infections may require at least 6 months of therapy. <b>Note:</b> Due to serious adverse effects (hepatotoxicity) and significant drug interactions, ketoconazole is seldom used in pediatric patients (<i>Red Book</i> [AAP], 2012); use should be reserved for patients who have failed or are intolerant to other antifungal therapies. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Fungal infections:</b> Oral: 200 to 400 mg once daily; continue therapy until active fungal infection has resolved (based on clinical and laboratory parameters); some infections may require at least 6 months of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment provided in manufacturer's labeling. Some clinicians suggest that no dosage adjustment is necessary in mild to severe impairment (Aronoff, 2007). Not dialyzable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge;2 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline hepatic impairment:</i> No dosage adjustment provided in manufacturer's labeling; use with extreme caution due to risks of hepatotoxicity; use is contraindicated with acute or chronic liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hepatotoxicity during treatment:</i> If ALT &gt;ULN or 30% above baseline (or if patient is symptomatic), interrupt therapy and obtain full hepatic function panel. Upon normalization of liver function, may consider resuming therapy if benefit outweighs risk (hepatotoxicity has been reported on rechallenge).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120786\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120610\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21098569\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362592.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5W75mT3RgKhF5vhx2WHO3Q8w==&amp;TOPIC_ID=16004\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362592.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503654\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer oral tablets 2 hours prior to antacids to prevent decreased absorption due to the high pH of gastric contents. Patients with achlorhydria should administer with acidic liquid (eg, soda pop).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120695\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503644\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible fungal infections, including blastomycosis, coccidioidomycosis, histoplasmosis, paracoccidioidomycosis, and chromomycosis in patients who have failed or who are intolerant to other antifungal therapies (FDA approved in ages &ge;2 years of age and adults). <b>Note:</b> Due to serious adverse effects (hepatotoxicity) and significant drug interactions, ketoconazole is seldom used in pediatric patients (<i>Red Book</i> [AAP], 2012); use should be reserved for patients who have failed or are intolerant to other antifungal therapies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120549\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nizoral may be confused with Nasarel, Neoral, Nitrol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120670\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Orthostatic hypotension, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Fatigue, insomnia, malaise, nervousness, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia, dermatitis, erythema, erythema multiforme, pruritus, skin rash, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hot flash, hyperlipidemia, menstrual disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, constipation, dysgeusia, dyspepsia, flatulence, increased appetite, nausea, tongue discoloration, upper abdominal pain, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Decreased platelet count</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Epistaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Alcohol intolerance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Acute generalized exanthematous pustulosis, adrenocortical insufficiency (&ge;400 mg/day), anaphylactic shock, anaphylaxis, angioedema, azoospermia, bulging fontanel (infants), cholestatic hepatitis, cirrhosis, decreased plasma testosterone (impaired at 800 mg/day), depression, erectile dysfunction (doses &gt;200-400 mg/day), gynecomastia, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, hypertriglyceridemia, hypersensitivity reaction, impotence, increased intracranial pressure (reversible), leukopenia, myopathy, papilledema, photophobia, prolonged Q-T interval on ECG, skin photosensitivity, suicidal tendencies, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120653\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ketoconazole or any component of the formulation; acute or chronic liver disease; coadministration with alprazolam, cisapride, colchicine, disopyramide, dofetilide, dronedarone, eplerenone, ergot alkaloids (eg, dihydroergotamine, ergometrine, ergotamine, methylergometrine), felodipine, HMG-CoA reductase inhibitors (eg, lovastatin, simvastatin), irinotecan, lurasidone, methadone, oral midazolam, nisoldipine, pimozide, quinidine, ranolazine, tolvaptan, triazolam</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Women of childbearing potential unless effective forms of contraception are used; coadministration with astemizole or terfenadine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120654\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: High doses of ketoconazole may depress adrenocortical function; returns to baseline upon discontinuation of therapy. Recommended maximum dosing should not be exceeded. Monitor adrenal function as clinically necessary, particularly in patients with adrenal insufficiency and in patients under prolonged stress (eg, intensive care, major surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fragility: In animal studies, increased long bone fragility with cases of fracture has been observed with high-dose ketoconazole. Careful dose selection may be advisable for patients susceptible to bone fragility (eg, postmenopausal women, elderly).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Cases of hypersensitivity reactions (including rare cases of anaphylaxis) have been reported; some reactions occurred after the initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Coadministration with HMG-CoA reductase inhibitors (eg, lovastatin, simvastatin) may increase the risk of myopathy. Concomitant use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sedation: Coadministration with midazolam, triazolam, and alprazolam may result in elevated plasma concentrations of the benzodiazepines, leading to prolonged hypnotic and sedative effects. Concomitant use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Achlorhydria: Absorption is reduced in patients with achlorhydria; administer with acidic liquids (eg, soda pop). Avoid concomitant use of drugs that decrease gastric acidity (eg, proton pump inhibitors, antacids, H<sub>2</sub>-blockers).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS infections: Ketoconazole has poor penetration into cerebral-spinal fluid and should not be used to treat fungal meningitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: <b>[US Boxed Warning]: Ketoconazole has been associated with hepatotoxicity, including fatal cases and cases requiring liver transplantation; some patients had no apparent risk factors for hepatic disease. Patients should be advised of the hepatotoxicity risks and monitored closely.</b> Toxicity was observed after a median duration of therapy of ~4 weeks, but has also been noted after as little as 3 days; may occur when patients receive high doses for short durations or low doses for long durations. Cases have been reported in patients treated with ketoconazole for onychomycosis, cutaneous dermatophyte infections, or Candida infections. Use with caution in patients with preexisting hepatic impairment, those on prolonged therapy and/or taking other hepatotoxic drugs concurrently. Hepatic dysfunction is typically (but not always) reversible upon discontinuation. Obtain liver function tests at baseline and frequently throughout therapy; serum ALT should be monitored weekly throughout therapy. Discontinue therapy for elevated hepatic enzymes that persist or worsen or if accompanied by signs/symptoms (eg, jaundice, nausea/vomiting, dark urine) of hepatic injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostate cancer: In European clinical trials of men with metastatic prostate cancer, fatalities were reported in a small number of study participants within 14 days of initiating high-dose ketoconazole (1,200 mg daily); a causal effect has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: <b>[US Boxed Warning]: Concomitant use with cisapride, disopyramide, dofetilide, dronedarone, methadone, pimozide, quinidine, and ranolazine is contraindicated due to the possible occurrence of life-threatening ventricular arrhythmias such as torsade de pointes.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Ketoconazole tablets are </b><b>not indicated for the treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections.</b> <b>Use only when other effective antifungal therapy is unavailable or not tolerated and the benefits of ketoconazole treatment are considered to outweigh the risks.</b> Ketoconazole oral tablets are only approved to treat systemic fungal infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120688\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2A6 (moderate), CYP2C19 (weak), CYP2C8 (weak), CYP2C9 (moderate), CYP3A4 (strong), P-glycoprotein/ABCB1, UGT1A1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120689\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16004&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: Ketoconazole (Systemic) may increase the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Ketoconazole (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl).  Management: Advise patients to avoid alcohol ingestion while taking ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Ketoconazole (Systemic) may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alitretinoin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALPRAZolam: Ketoconazole (Systemic) may increase the serum concentration of ALPRAZolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Ketoconazole (Systemic) may enhance the QTc-prolonging effect of Amifampridine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Ketoconazole (Systemic). Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Antihepaciviral Combination Products. Specifically, ketoconazole may increase serum concentrations of paritaprevir. Management: Limit the dose of ketoconazole to 200 mg per day in patients taking antihepaciviral combination products. Additionally, monitor for increased ketoconazole effects/toxicities and for increased paritaprevir effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Apixaban.  Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 10 mg twice daily, and avoiding in patients who would otherwise receive 2.5 mg twice daily. Canadian labeling lists any combined use as contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Please refer to the full interaction monograph for details concerning the recommended dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artesunate: CYP2A6 Inhibitors may decrease serum concentrations of the active metabolite(s) of Artesunate. CYP2A6 Inhibitors may increase the serum concentration of Artesunate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Astemizole: Ketoconazole (Systemic) may enhance the QTc-prolonging effect of Astemizole. Ketoconazole (Systemic) may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May enhance the adverse/toxic effect of Ketoconazole (Systemic). Specifically, there is a theoretical potential for additive effects on reducing endogenous steroid concentrations. Ketoconazole (Systemic) may increase the serum concentration of AtorvaSTATin. Management: Administer ketoconazole with atorvastatin cautiously, and monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities). Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: Ketoconazole (Systemic) may increase the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bictegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Blonanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: Ketoconazole (Systemic) may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit maximum adult ketoconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in ketoconazole concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with a strong CYP3A4 inhibitor; reduce to 25% of usual if used with both a moderate CYP3A4 inhibitor and a CYP2D6 inhibitor, or if a strong CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If combination cannot be avoided, reduce the brigatinib dose by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromocriptine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabazitaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.  Management: Concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided when possible.  If such a combination must be used, consider a 25% reduction in the cabazitaxel dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.  Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcifediol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.<b> Exceptions: </b>Clevidipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabidiol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: Ketoconazole (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, ketoconazole may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products.  Management: Advise patients to avoid alcohol ingestion while taking ketoconazole.  Liquid formulations of carbcisteine-containing products contain alcohol, which may interact with ketoconazole in some patients.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cariprazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cariprazine.  Management: Cariprazine dose reductions of 50% are required; specific recommended management varies slightly for those stable on cariprazine versus those just starting cariprazine.  See prescribing information or full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib.  Management:  If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest 150 mg).  Resume the prior ceritinib dose after cessation of the strong CYP3A4 inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving strong inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: Ketoconazole (Systemic) may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit ketoconazole to a maximum adult dose of 200 mg/day in patients being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir combination product. Dosing recommendations for other cobicistat-containing products are not available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Copanlisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Copanlisib.  Management: If concomitant use of copanlisib and strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg. Monitor patients for increased copanlisib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Orally inhaled fluticasone propionate with a strong CYP3A4 inhibitor is not recommended.<b> Exceptions: </b>Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Systemic). <b> Exceptions: </b>MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic). Fluconazole and isavuconazonium considerations are addressed in separate monographs. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inhibitors): CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); AmLODIPine; Benzhydrocodone; Buprenorphine; Gefitinib; HYDROcodone; Praziquantel; Telithromycin; Vinorelbine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Ketoconazole (Systemic) may increase the serum concentration of Dabigatran Etexilate.  Management: Dose reductions and/or avoidance of this combination may be necessary. Specific recommendations vary by international labeling, renal function, and indication for dabigatran. Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dabrafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daclatasvir.  Management: Decrease the daclatasvir dose to 30 mg once daily if combined with a strong CYP3A4 inhibitor.  No dose adjustment is needed when daclatasvir is used with darunavir/cobicistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Darunavir. Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.  Management: This combination should be avoided; consider reducing dasatinib dose if a strong CYP3A4 inhibitor must be used. If using dasatinib 70 mg/day or 100 mg/day, consider reduction to 20 mg/day; if using dasatinib 140 mg/day, consider reduction to 40 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Delamanid.  Management: Increase electrocardiogram (ECG) monitoring frequency if delamanid is combined with strong CYP3A4 inhibitors because the risk for QTc interval prolongation may be increased. Continue frequent ECG assessments throughout the full delamanid treatment period.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dexamethasone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dihydroergotamine: Ketoconazole (Systemic) may increase the serum concentration of Dihydroergotamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: Ketoconazole (Systemic) may increase the serum concentration of Disopyramide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOCEtaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOCEtaxel.  Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Ketoconazole (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: Ketoconazole (Systemic) may increase the serum concentration of Elbasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat.  Management: Use should be avoided under some circumstances.  See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Ketoconazole (Systemic) may increase the serum concentration of Elvitegravir.  Management: Limit ketoconazole to a maximum dose of 200 mg/day in patients who are being treated with an elvitegravir-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Emedastine (Systemic): Ketoconazole (Systemic) may increase the serum concentration of Emedastine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Ketoconazole (Systemic) may increase the serum concentration of Eplerenone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergoloid Mesylates: Ketoconazole (Systemic) may increase the serum concentration of Ergoloid Mesylates. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergonovine: Ketoconazole (Systemic) may increase the serum concentration of Ergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergotamine: Ketoconazole (Systemic) may increase the serum concentration of Ergotamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estazolam: Ketoconazole (Systemic) may increase the serum concentration of Estazolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eszopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eszopiclone.  Management: Limit the eszopiclone dose to 2 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased eszopiclone effects and toxicities (eg, somnolence, drowsiness, CNS depression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etizolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Etizolam.  Management: Consider use of lower etizolam doses when using this combination; specific recommendations concerning dose adjustment are not available.  Monitor clinical response to the combination closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs. Etravirine may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole.  Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evogliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felodipine: Ketoconazole (Systemic) may increase the serum concentration of Felodipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fexofenadine: Ketoconazole (Systemic) may increase the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fimasartan: Ketoconazole (Systemic) may increase the serum concentration of Fimasartan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Fingolimod. Ketoconazole (Systemic) may increase the serum concentration of Fingolimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).  Management: Use of orally inhaled fluticasone propionate with strong CYP3A4 inhibitors is not recommended.  Use of orally inhaled fluticasone furoate with strong CYP3A4 inhibitors should be done with caution.  Monitor patients using such a combination more closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day ketoconazole may also require dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: Ketoconazole (Systemic) may increase the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Ketoconazole (Systemic). Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ibrutinib.  Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Idelalisib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imidafenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imidafenacin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Ketoconazole (Systemic) may increase the serum concentration of Indinavir. Indinavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with ketoconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: UGT1A1 Inhibitors may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Strong) may increase isavuconazole serum concentrations.  Management: Combined use is considered contraindicated per US labeling. Lopinavir/ritonavir (and possibly other uses of ritonavir doses less than 400 mg every 12 hours) is treated as a possible exception to this contraindication despite strongly inhibiting CYP3A4.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May decrease the serum concentration of Ketoconazole (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib adult dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lercanidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levobupivacaine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomilnacipran: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.  Management: Do not exceed a maximum adult levomilnacipran dose of 80 mg/day in patients also receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: Ketoconazole (Systemic) may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan. Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of Ketoconazole (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macitentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities. Manidipine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MedroxyPROGESTERone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MedroxyPROGESTERone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Ketoconazole (Systemic) may increase the serum concentration of Methadone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylergonovine: Ketoconazole (Systemic) may increase the serum concentration of Methylergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose reduction in patients receiving strong CYP3A4 inhibitors and monitor for increased steroid related adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam: Ketoconazole (Systemic) may increase the serum concentration of Midazolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midostaurin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin.  Management: Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MiFEPRIStone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 600 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Ketoconazole (Systemic) may increase the serum concentration of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirodenafil.  Management: Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Monitor for increased mirodenafil effects/toxicities with the use of this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May decrease the serum concentration of Ketoconazole (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Combined Inhibitors of CYP3A4 and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olaparib.  Management: Avoid use of strong CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxybutynin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.  Management: Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Parecoxib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs. Phenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic).  Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimavanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimavanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias.  Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperaquine: CYP3A4 Inhibitors (Strong) may enhance the QTc-prolonging effect of Piperaquine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Piperaquine.  Management: Avoid the concomitant use of piperaquine and strong CYP3A4 inhibitors when possible. If this combination cannot be avoided, frequent ECG monitoring is recommended due to the increased risk for QTc prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PONATinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.  Management: Per ponatinib U.S. prescribing information, the adult starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pranlukast: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Praziquantel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QUEtiapine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.  Management: In quetiapine treated patients, reduce the quetiapine dose to one sixth of the regular dose following strong CYP3A4 inhibitor initiation. In patients receiving strong CYP3A4 inhibitors, initiate quetiapine at the lowest dose and up-titrate as needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Radotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine. Fluconazole and isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Reboxetine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide.  Management: The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retapamulin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.  Management: Avoid this combination in patients less than 2 years old.  No action is required in other populations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ribociclib.  Management: Avoid use of ribociclib with strong CYP3A4 inhibitors when possible; if combined use cannot be avoided, reduce ribociclib dose to 400 mg once daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected. Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic).  Management: Avoid these combinations when possible.  Voriconazole and isavuconazonium are considered contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Ketoconazole (Systemic) may increase the serum concentration of Rilpivirine. Rilpivirine may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Ketoconazole (Systemic) may increase the serum concentration of Riociguat.  Management: Consider starting with a reduced riociguat dose of 0.5 mg three times a day.  Patients receiving such a combination should also be monitored extra closely for signs or symptoms of hypotension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Ketoconazole (Systemic). Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rupatadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Saquinavir. Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: Ketoconazole (Systemic) may increase the serum concentration of Sildenafil.  Management: Concurrent ketoconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Ketoconazole (Systemic) may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: The manufacturer recommends not exceeding 5 mg daily of solifenacin during concomitant therapy with ketoconazole, or other potent CYP3A4 enzyme inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Ketoconazole (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUFentanil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: Consider a reduced dose of sunitinib (minimum of 37.5 mg daily) during concomitant use. Concurrent use with itraconazole is not recommended per itraconazole labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Ketoconazole (Systemic) may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required when taken with ketoconazole due to elevated plasma concentrations of tacrolimus.  Monitor tacrolimus concentrations and clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical). Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: Ketoconazole (Systemic) may increase the serum concentration of Tadalafil. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tasimelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: CYP2A6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tegafur. Specifically, CYP2A6 inhibitors may inhibit the conversion of tegafur into its active metabolite, 5-fluorouracil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Ketoconazole (Systemic) may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Ketoconazole (Systemic).  Management: Doses of ketoconazole greater than 200 mg/day are not recommended in patients receiving telaprevir.  Use extra caution when using these drugs in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: Ketoconazole (Systemic) may increase the serum concentration of Telithromycin. Telithromycin may increase the serum concentration of Ketoconazole (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Temsirolimus dose adjustments will likely be needed when starting/stopping/changing ketoconazole.  Clinical data suggest temsirolimus (adult) dose reductions of around 50% should be considered, but specific guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: Ketoconazole (Systemic) may increase the serum concentration of Teneligliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Ketoconazole (Systemic) may enhance the QTc-prolonging effect of Terfenadine. Ketoconazole (Systemic) may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tezacaftor.  Management: When combined with strong CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be administered in the morning, twice a week, approximately 3 to 4 days apart. No evening doses of ivacaftor (150 mg) alone should be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Ketoconazole (Systemic). Management: Limit ketoconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended adult dose of tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triazolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triazolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Udenafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combo should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine.  Management: Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vardenafil: Ketoconazole (Systemic) may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 5 mg per 24 hours  in patients receiving ketoconazole 200 mg/day, and a maximum of 2.5 mg per 24 hours in patients receiving ketoconazole 400 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Venetoclax.  Management: These combinations are contraindicated during venetoclax initiation and ramp-up. In patients receiving steady venetoclax doses after completing ramp-up, reduce the venetoclax by at least 75% if strong CYP3A4 inhibitor use cannot be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg daily in patients receiving strong CYP3A4 inhibitors. The original vilazodone dose can be resumed following discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vindesine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinorelbine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Ketoconazole (Systemic) may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: Ketoconazole (Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving ketoconazole and monitor for increased zolpidem effects/toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.  Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120693\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ketoconazole peak serum levels may be prolonged if taken with food. Management: May administer with food or milk to decrease GI adverse effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120649\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120650\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Based on limited data, an increased risk of adverse events in pregnancy has not been observed (Amado 1990; Berwaerts 1999; Boronat 2011; Carter 2008; Costenaro 2015; Kazy 2005; Molgaard-Nielsen 2013; Prebtani 2000). However, because ketonconazole exhibits antiandrogenic effects, there is a theoretical risk for the impairment of sex organ differentiation following exposure to ketonconazole during critical times of organogenesis (Pilmis 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Ketoconazole is approved for the treatment of blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis in patients who have failed or who are intolerant to other antifungal therapies. When treatment of systemic fungal infections is needed in pregnant women, alternative antifungal agents should be used (Chapman 2008; Galgiani 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Ketoconazole is an effective and recommended agent for the medical treatment of Cushing syndrome (Nieman 2015). Cushing syndrome during pregnancy is associated with neonatal and maternal morbidity and mortality (Aron 1990; Lindsay 2005). In pregnant women with Cushing syndrome, the treatment of choice is surgical intervention or, in patients not eligible for surgical intervention, medical therapy with metyrapone (Nieman 2015). Some experts recommend reserving ketoconazole for the treatment of pregnant women with Cushing syndrome who require emergent medical therapy but cannot tolerate the preferred treatment (Lindsay 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501728\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic function tests (baseline and frequently during therapy), including weekly ALT for the duration of treatment, adrenal function (as clinically necessary)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120696\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alters the permeability of the cell wall by blocking fungal cytochrome P450; inhibits biosynthesis of triglycerides and phospholipids by fungi; inhibits several fungal enzymes that results in a build-up of toxic concentrations of hydrogen peroxide; for management of prostate cancer, ketoconazole inhibits androgen synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120698\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Well into inflamed joint fluid, saliva, bile, urine, sebum, cerumen, feces, tendons, skin and soft tissue, and testes; crosses blood-brain barrier poorly; only negligible amounts reach CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~99% (mainly albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Partially hepatic via CYP3A4 to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Decreases as gastric pH increases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Biphasic: Initial: 2 hours; Terminal: 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1-2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (57%); urine (13%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120789\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 20 mg/mL oral suspension may be made with tablets and one of three different vehicles (a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;, or a 1:4 mixture of cherry syrup and Simple Syrup, NF). Crush twelve 200 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;.  Stable for 60 days.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120788\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ketoconazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $378.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961982\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Azoplus (ZW);</li>\n      <li>Bonazol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Clarazole (AE, KW, QA);</li>\n      <li>Clarzole (BH);</li>\n      <li>Dermazol (UA);</li>\n      <li>Dexazol (ID);</li>\n      <li>Dezor (ZW);</li>\n      <li>Diazon (SG, TH);</li>\n      <li>Formyco (SG);</li>\n      <li>Funet (ID);</li>\n      <li>Fungazol (TH);</li>\n      <li>Fungicid (ET);</li>\n      <li>Fungicide (IN);</li>\n      <li>Funginox (TH);</li>\n      <li>Fungistab (ET);</li>\n      <li>Fungium (CL, PY);</li>\n      <li>Fungizol (PH);</li>\n      <li>Fungoral (GR, NO, SE);</li>\n      <li>Fungotab (LK);</li>\n      <li>Keezole (BD);</li>\n      <li>Kenazol (TH);</li>\n      <li>Ketazol (ZA);</li>\n      <li>Ketoconazol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ketodar (JO);</li>\n      <li>Ketona (TW);</li>\n      <li>Ketoral (ET);</li>\n      <li>Ketovid (PH);</li>\n      <li>Kezole (LK);</li>\n      <li>Micoral (AR, BR);</li>\n      <li>Muzoral (ID);</li>\n      <li>Mycoral (LK);</li>\n      <li>Nizoral (AE, BB, BD, BE, BH, BM, BS, CH, CN, CO, CY, CZ, DK, EC, EE, EG, ET, FI, FR, GY, HK, ID, IL, IT, JM, JO, KW, LB, NL, NZ, PE, PH, PR, PY, QA, RU, SA, SG, SR, TH, TR, TT, TW, UY, VE, ZA);</li>\n      <li>Phytoral (ZW);</li>\n      <li>Picamic (ID);</li>\n      <li>Pristinex (MY);</li>\n      <li>Spike (KR);</li>\n      <li>Sporaxyl (TH);</li>\n      <li>Tinuvin (TW);</li>\n      <li>Vavo (AE, BH, KW, QA, SA);</li>\n      <li>Zoralin (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amado JA, Pesquera C, Gonzalez EM, Otero M, Freijanes J, Alvarez A. Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. <i>Postgrad Med J</i>. 1990;66(773):221-223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/2362890/pubmed\" target=\"_blank\" id=\"2362890\">2362890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berwaerts J, Verhelst J, Mahler C, Abs R. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. <i>Gynecol Endocrinol</i>. 1999;13(3):175-182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/10451809/pubmed\" target=\"_blank\" id=\"10451809\">10451809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boronat M, Marrero D, L&oacute;pez-Plasencia Y, Barber M, Schamann Y, N&oacute;voa FJ. Successful outcome of pregnancy in a patient with Cushing's disease under treatment with ketoconazole during the first trimester of gestation. <i>Gynecol Endocrinol</i>. 2011;27(9):675-677.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/20923280/pubmed\" target=\"_blank\" id=\"20923280\">20923280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carter TC, Druschel CM, Romitti PA, et al. Antifungal drugs and the risk of selected birth defects. <i>Am J Obstet Gynecol</i>. 2008;198(2):191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/18226621/pubmed\" target=\"_blank\" id=\"18226621\">18226621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al, &ldquo;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2008, 46(12):1801-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costenaro F, Rodrigues TC, de Lima PB, Ruszczyk J, Rollin G, Czepielewski MA. A successful case of Cushing's disease pregnancy treated with ketoconazole. <i>Gynecol Endocrinol</i>. 2015;31(3):176-178.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/25561184/pubmed\" target=\"_blank\" id=\"25561184\">25561184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. <i>Antimicrob Agents Chemother</i>. 1981;19(6):1073-1074.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/6267997/pubmed\" target=\"_blank\" id=\"6267997\">6267997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al, &ldquo;Coccidioidomycosis,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(9):1217-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/16206093/pubmed\" target=\"_blank\" id=\"16206093\">16206093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kazy Z, Puh&oacute; E, Czeizel AE. Population-based case-control study of oral ketoconazole treatment for birth outcomes. <i>Congenit Anom (Kyoto)</i>. 2005;45(1):5-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/15737124/pubmed\" target=\"_blank\" id=\"15737124\">15737124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK. Cushing's syndrome during pregnancy: personal experience and review of the literature. <i>J Clin Endocrinol Metab</i>. 2005;90(5):3077-3083.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/15705919/pubmed\" target=\"_blank\" id=\"15705919\">15705919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;lgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. <i>N Engl J Med</i>. 2013;369(9):830-839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/23984730/pubmed\" target=\"_blank\" id=\"23984730\">23984730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moretti ME, Ito S, and Koren G, &ldquo;Disposition of Maternal Ketoconazole in Breast Milk,&rdquo; <i>Am J Obstet Gynecol</i>, 1995, 173(5):1625-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/7503214/pubmed\" target=\"_blank\" id=\"7503214\">7503214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi: 10.1210/jc.2015-1818.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/26222757/pubmed\" target=\"_blank\" id=\"26222757\">26222757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. <i>J Antimicrob Chemother</i>. 2015;70(1):14-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/25204341/pubmed\" target=\"_blank\" id=\"25204341\">25204341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pont A, Graybill JR, Craven PC, et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. <i>Arch Intern Med</i>. 1984;144(11):2150-2153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/6093722/pubmed\" target=\"_blank\" id=\"6093722\">6093722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prebtani AP, Donat D, Ezzat S. Worrisome striae in pregnancy. <i>Lancet</i>. 2000;355(9216):1692.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/10905246/pubmed\" target=\"_blank\" id=\"10905246\">10905246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santen RJ, Van den Bossche H, Symoens J, Brugmans J, DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. <i>J Clin Endocrinol Metab</i>. 1983;57(4):732-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/6309882/pubmed\" target=\"_blank\" id=\"6309882\">6309882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&uuml;rmeyer T, Nieschlag E. Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis. <i>Acta Endocrinol (Copenh)</i>.1984;105(2):275-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketoconazole-systemic-pediatric-drug-information/abstract-text/6320571/pubmed\" target=\"_blank\" id=\"6320571\">6320571</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16004 Version 188.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8120384\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8120609\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10501727\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10503653\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8120786\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8120610\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F21098569\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10503654\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8120695\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10503644\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8120549\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8120670\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8120653\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8120654\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8120688\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8120689\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8120693\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8120649\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8120650\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10501728\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8120696\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8120698\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F8120789\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8120788\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961982\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16004|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ketoconazole-systemic-drug-information\" class=\"drug drug_general\">Ketoconazole (systemic): Drug information</a></li><li><a href=\"topic.htm?path=ketoconazole-systemic-patient-drug-information\" class=\"drug drug_patient\">Ketoconazole (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}